a blood test for the early detection of pancreatic cancer in individuals at risk for developing familial or hereditary pancreatic ductal adenocarcinoma (PDAC)
See what financial assistance programs and prompt pay discounts are available.
Blood drawn at a local Quest Diagnostics Patient Service Center.
Actionable results delivered 5 to 7 business days of specimen receipt.
What does early detection mean to you?
The IMMray PanCan-d test measures 9 biomarkers including CA19-9 to detect pancreatic ductal adenocarcinoma (PDAC) in a serum sample with 92% sensitivity and 99% specificity.
LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment determination implying a…
LUND, SWEDEN – Immunovia today announced results from the PanFAM-1 study. The PanFAM-1 study is a prospective, multi-center, investigational study, designed to assess the performance…
Pancreatic cancer is a low incidence disease with a high mortality rate. Most patients (80%) are diagnosed with late stage disease when the cancer has already metastasized and treatment options are limited. But, if detected early, 5-year survival rates jump from just 3% in late stage disease to 42%.
I IMMagine my children and grandchildren won’t have to worry about pancreatic cancer; I imagine peace of mind. **
Marilyn V., Meriden, CT
The average person’s risk for developing pancreatic cancer is very low, with a lifetime risk of just 1.6%. But, a strong family history of pancreatic cancer or certain germline genetic mutations, could make the risk higher.
Order a test
Download the IMMray PanCan-d test requisition.
Order a test, check on status of existing test orders, and access results.
View your invoice and process payments online.
* ”Early detection” signifying detection of stage I and II pancreatic ductal adenocarcinoma (PDAC).
** “Direct quote from person impacted by pancreatic cancer who was asked “What does early detection mean to you?”